Drug Profile
Research programme: immunotherapies - PDS Biotechnology Corporation
Alternative Names: PDS-0104; PDS0102A; PDS0102BLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator PDS Biotechnology Corporation
- Developer National Cancer Institute (USA); PDS Biotechnology Corporation
- Class Antineoplastics; Antivirals; Immunotherapies
- Mechanism of Action Immunomodulators; Immunosuppressants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioma; Malignant melanoma; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Glioma in USA (SC, Injection)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (SC, Injection)
- 28 May 2022 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (SC, Injection)